Mayne Pharma Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Mayne Pharma Group şirketinin toplam hissedar öz sermayesi A$454.2M ve toplam borcu A$31.6M olup, bu da borç-öz sermaye oranını 7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$1.1B ve A$689.0M dir.

Anahtar bilgiler

7.0%

Borç/özkaynak oranı

AU$31.64m

Borç

Faiz karşılama oranı	n/a
Nakit	AU$149.28m
Eşitlik	AU$454.19m
Toplam yükümlülükler	AU$688.99m
Toplam varlıklar	AU$1.14b

Son finansal sağlık güncellemeleri

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Sep 01

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Dec 03

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Dec 01

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Apr 12

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MYX 'nin kısa vadeli varlıkları ( A$460.6M ) kısa vadeli yükümlülüklerini ( A$313.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: MYX şirketinin kısa vadeli varlıkları ( A$460.6M ) uzun vadeli yükümlülüklerini ( A$375.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MYX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: MYX 'nin borç/öz sermaye oranı son 5 yılda 36.5% seviyesinden 7% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MYX şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: MYX un, serbest nakit akışı her yıl % 49.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Mayne Pharma Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Price target decreased by 12% to AU$6.09

New major risk - Financial position

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

New minor risk - Profitability

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Consensus estimates of losses per share improve by 13%

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Consensus estimates of losses per share improve by 13%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Consensus revenue estimates fall by 19%

Price target decreased by 24% to AU$3.86

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Consensus revenue estimates fall by 11%

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Consensus forecasts updated

Price target decreased to AU$0.37

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Price target decreased to AU$0.40

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

Price target increased to AU$0.43

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Price target decreased to AU$0.36

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 97%

Mayne Pharma Expands U.S Dermatology Portfolio

Price target increased to AU$0.48

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Independent Non-Executive Director recently bought AU$137k worth of stock

Price target decreased to AU$0.42

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt